Overview

* Sangamo Q2 revenue rises to $18.3 mln but missed analyst expectations, per LSEG data

* Net loss of $0.08 per share beats analyst estimates, per LSEG data

Outlook

* Company reiterates 2025 operating expenses guidance of $135 mln to $155 mln

Result Drivers

* NEUROLOGY PIPELINE - Initiation of first clinical site for STAND study in chronic neuropathic pain marks entry into clinical-stage neurology

* EQUITY OFFERING - Raised $21 mln in net proceeds from equity offering, contributing to financial activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $18.31 $31.70

Revenue mln mln (5

Analysts

)

Q2 EPS Beat -$0.08 -$0.13

(4

Analysts

)

Q2 Net -$19.99

Income mln

Q2 $33 mln

Adjusted

Operatin

g

Expenses

Q2 $36.20

Operatin mln

g

Expenses

Q2 -$17.86

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Sangamo Therapeutics Inc ( SGMO ) is $2.00, about 73.5% above its August 6 closing price of $0.53

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)